期刊文献+

博莱霉素与博莱霉素A5诱导小鼠肺组织损伤的差异 被引量:1

Different Damaging Effect of Bleomycin and Bleomycin-A5 on Lung Tissues
下载PDF
导出
摘要 目的探讨静脉注射博莱霉素(BLM)和博莱霉素A5(BLM-A5)对小鼠肺组织损伤的不同作用。方法8周龄雌性C57BL/6小鼠49只,随机分为BLM组19只、BLM-A5组20只和对照组10只,分别经尾静脉一次性注射BLM 150 mg/kg、BLM-A5 150 mg/kg和生理盐水。观察每组小鼠体重、生存率,肺组织病理改变及肺组织羟脯胺酸的含量。结果①BLM组和BLM-A5组小鼠最低体重分别为静脉注射处置前的65.46%和66.87%,均较对照组明显降低(P值均小于0.001)。②BLM组、BLM-A5组和对照组小鼠的生存率分别为:43%、55%和100%。③BLM组小鼠注射处置后28 d,在胸膜下及血管周围形成广泛、稳定的间质纤维化病理改变,而BLM-A5组无明显纤维化形成。BLM组与BLM-A5组、正常组比较,肺纤维化病理评分均明显增高(P值均小于0.001)。④BLM-A5组和对照组注射处置后28 d,右肺羟脯氨酸含量分别为471.6±49.4 nmol和405.0±74.6 nmol,两组间无统计学差异。BLM组为978.4±106.1 nmol,与BLM-A5组、对照组比较分别存在显著性差异(P值均小于0.01)。结论静脉注射BLM与BLM-A5,对小鼠肺组织损伤的作用存在着明显的差异,BLM可导致肺间质形成广泛的纤维化,而BLM-A5仅引起轻微的肺组织损伤,不形成明显的间质纤维化。 Objective To study the difference of bleomycin and bleomycin-A5 induced lung tissue injury in mice. Methods Forty nine C57BL/6 mice (female, 8 wk of age, 17 to 20 g body weight) were randomly divided into BLM, BLM-A5 and control groups. The mice received injection of bleomycin ( 150 mg/kg), bleomycin-A5 ( 150 mg/kg) and normal saline via the tail vein, respectively. The body weight, survival rate, pathological changes of lung tissues and hydroxyproline content in lung tissues were analyzed. Results (1) The mice of the BLM and BLM-A5 groups lost their body weight 34.54% and 33.13% after treatment, respectively, significantly decreased in comparison with that of the control group. (2) The survival rate of the BLM and BLM-A5 groups were 43% and 55%, respectively, significantly decreased in comparison with that of the control group ( 100% ). (3) 28 days after drug injection, fibrosis was widely and stably formed in the subpleura and around blood vessels in the BLM-treated mice, but not in the BLM-A5 group. The pathological score of pulmonary fibrosis in the BLM group was significantly higher than that in BLM-A5 and control groups (both were P 〈 0.001 ). (4) 28 days after injection, the hydroxyproline content in the lung tissue in the BLM, BLM-A5 and control groups were 978.4 ± 106.1 nmol, 471.6 ± 49.4 nmol and 405.0 ± 74.6 nmol, respectively. It was significantly increased in the BLM group than that in the BLM-A5 and control groups ( P 〈 0.01 ). Conclusions There are significantly different effects of BLM and BLM-A5 on the process of lung tissue injury in mice. BLM induces widely spread pulmonary fibrosis, but BLM-A5 only causes mild pulmonary damage, and does not induce remarkable fibrosis.
出处 《中国实验动物学报》 CAS CSCD 2007年第5期326-329,I0001,共5页 Acta Laboratorium Animalis Scientia Sinica
基金 国家自然科学基金资助项目(3010007630570812) 辽宁省自然科学基金资助项目(20042085)基金资助
关键词 小鼠 近交C57BL 博莱霉素 博莱霉素A5 肺纤维化 肺损伤 C57BL/6 mouse Bleomycin Bleomycin-A5 Pulmonary fibrosis Lung injury
  • 相关文献

参考文献11

  • 1孙燕,周际昌,王子平.抗肿瘤药[A].见:陈新谦:新编药物学[M].第15版.北京:人民卫生出版社,2004.677-678.
  • 2Ashcroft T, Simpson J, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale[J]. J Clin Pathol, 1988, 41:467 - 470.
  • 3Zhang XY, Shimura S, Masuda T, et al. Antisense oligonucleotides to NF-κB improve the survival in Bleomycin-induced pneumopathy of mouse[J]. Am J Respir Crit Care Med, 2000, 162(4): 1561 - 1568.
  • 4Green D, Reagan K. Determination of hydroxyproline by high pressure liquid chromatography[ J ]. Anal Biochem, 1992, 201 ; 265 - 269.
  • 5Gharaee M, Ullenbruch M, Phan SH. Animal models of pulmonary fibrosis[J]. Methods Mol Med, 2005, 117:251 -259.
  • 6Felix C, Jack G, Geoffrey J. Pulmonary fibrosis searching for model answers[J]. Am J Respir Cell Mol Biol, 2005, 33:9 - 13.
  • 7Harrison J, Laso J. Plasma and pulmonary pharmacokinetics of bleomycin in murine strains that are sensitive and resistant to bleomycin-induced pulmonary fibrosis [ J ]. J Pharmacol Exp Ther, 1988, 247(3) : 1052 - 1058.
  • 8Harrison J, Lazo J. High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis [J]. J Pharmacol Exp Ther, 1987, 243(3) : 1185 - 1194.
  • 9张晓晔,志村早苗,增田辙,齐藤宏树.博莱霉素静脉注射制备小鼠肺间质纤维化模型[J].中国实验动物学报,2007,15(4):241-244. 被引量:11
  • 10张晓晔,周妍,刘卫青,赵立,李胜歧.核因子κB反义寡核苷酸对博莱霉素致小鼠肺间质纤维化形成及白细胞介素4表达的影响[J].中华医学杂志,2007,87(3):195-199. 被引量:8

二级参考文献29

  • 1尹红军,曹书颖,关继涛,底胜峰.博莱霉素致大鼠肺纤维化Th1/Th2细胞因子变化及卡介菌多糖核酸的影响[J].国外医学(呼吸系统分册),2005,25(5):321-324. 被引量:10
  • 2李健,牛建昭,王继峰,李彧,Jack Gauldie,贲长恩.AdTGF-β_1^(223/225)气管内注射制备大鼠肺间质纤维化动物模型[J].中国实验动物学报,2006,14(1):5-7. 被引量:9
  • 3American Thoracic Society (ATS).Idiopathic pulmonary fibrosis:diagnosis and treatment.Am J Respir Crit Care Med,2000,161:646-664.
  • 4Lukacs NW,Hogaboam C,Chensue SW,et al.Type1/Type2 cytokine paradigm and the progression of pulmonary fibrosis.Chest,2001,120 (1 Suppl):5 s-8s.
  • 5Neurath MF,Pettersson S,Büschenfelde KHM,et al.Local administration of antisense phosphorothioate to the p65 subunit of NF-κB abrogates established experimental colitis in mice.Nature Med,1996,2:998-1004.
  • 6Green GD,Reagan K.Determination of hydroxyproline by high pressure liquid chromatography.Anal Biochem,1992,201:265-269.
  • 7张晓晔 侯显明.转录因子NF—κB与非特异性炎症[J].国外医学:呼吸系统分册,2000,20:41-42.
  • 8Gozal E,Ortiz L,Lasky J,et al.NF-κB activation in the pathogenesis of bleomycin-induced lung injury.Am J Respir Crit Care Med,1998,157:A265.
  • 9Castranova V.Effect of inhaled crystalline silica in a rat model:time course of pulmonary reactions.Mol Cell Biochem,2002,234-235:177-184.
  • 10Sime PJ,O'Reilly KM.Fibrosis of the lung and other tissues:new concepts in pathogenesis and treatment.Clin Immunol,2001,99:308-319.

共引文献17

同被引文献18

  • 1徐叔云,卞如濂.药理实验方法学[M].3版.北京:人民卫生出版社,2006:759.
  • 2陈新谦,金有豫.新编药物学[M].15版.北京:人民卫生出版社.2004:17.
  • 3K aunisto J , Kelloniem i K , Sutinen E , et al. R e-evaluationof diagnostic param eters is crucial for obtaining accuratedata on idiopathic pulm onary fibrosis [J] . BMCPulm M e d ,2 0 1 5 ,1 5 :92.
  • 4W ells A U ,C o stab el U , Poletti V , et al. Challenges inIPF diagnosis, current m anagem ent and future perspectives[J]. Sarcoidosis Vase Diffuse Lung D is,2015, 32(Suppl 1) :28-35.
  • 5B endstrup E ,M aher T M ,M anali E D ,e t al. Challengesin the classification of fibrotic IL D [J]. Sarcoidosis VaseDiffuse Lung D is, 2 01 5,32 (Suppl 1) : 4-9.
  • 6Jacob J , H ansell D M. H R C T of fibrosing lung disease[J]. R espirology,2 0 1 5 ,2 0 (6 ) :859-872.
  • 7Behr J , K reuter M , H oeper M M , et al. M anagem ent ofpatients w ith idiopathic pulm onary fibrosis in clinicalpractice : the IN SIG H T S-IPF reg istry [J]. E ur R espir J ,2 0 1 5 ,4 6 (1 ):186-196.
  • 8Pezzuto G ,Claroni G , Puxeddu E , et al. Structured m ultidisciplinarydiscussion of H R C T scans for IP F /U IP diagnosismay result in indefinite o utco m es[J]. SarcoidosisV ase Diffuse Lung Dis ,2 0 1 5 ,3 2 (1 ) : 32-36.
  • 9M oeller A , A sk K , W arburton D , et al. T he bleomycinanimal m odel: a useful tool to investigate treatm ent optionsfor idiopathic pulm onary fibrosis- [J]. Int J BiochemCell B iol,2 0 0 8 ,4 0 (3 ) : 362-382.
  • 10Robbe A , T assin A , C arpentier J , et al. Intratrachealbleom ycin aerosolization: the best route of adm inistrationfor a scalable and hom ogeneous pulm onary fibrosisrat model? [J]. Biomed Res In t, 2015 : 198418.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部